From: Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease
Cost (U.S.$) | LYs | QALYs | Probability of each outcome | |
---|---|---|---|---|
Lifetime discounted costs and benefits by diagnostic outcome | ||||
AD | ||||
True-positive | $298,632 | 6.781 | 2.916 | 8.9% |
False-negative | $308,586 | 6.555 | 2.660 | 3.8% |
Not AD | ||||
False-positive | $294,732 | 9.157 | 5.048 | 5.2% |
True-negative | $283,387 | 9.157 | 5.048 | 82.1% |
Lifetime discounted costs and benefits by diagnostic strategy | ||||
Do nothing | $286,587 (244,438 to 337,270) | 4.745 (3.88 to 5.42) | ||
Biomarker analysis (BM) | $286,752 (244,044 to 337,163) | 4.760 (3.89 to 5.44) | ||
Incremental (BM vs. do nothing) | $165 (−1865 to 1625) | 0.015 (−0.011 to 0.051) | ||
Incremental cost-effectiveness ratio ($ per QALY gained) | $11,032a |